Quantification of 4-methylaminoantipyrine, the active metabolite of dipyrone, in human plasma

Bioanalysis

Volumn 1, Issue 2, 2009, Pages 293-298

  Ojha, Ashwini ^a   Rathod, Rajeshwari ^a   Padh, Harish ^a  

^a Research Development Centre Thaltej   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRONE; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; NORAMIDOPYRINE; PHENAZONE; PROPYPHENAZONE;

ARTICLE; BLOOD; CALIBRATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; REPRODUCIBILITY; STANDARD; TANDEM MASS SPECTROMETRY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRINE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DIPYRONE; DRUG STABILITY; HUMANS; MASS SPECTROMETRY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 79957966040     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.26     Document Type: Article

References (15)

1. Hinz B, Cheremina O, Bachmakow J et al. Dipyrone elicits substantial inhibition of peripheral cyclooxegenases in humans: new insights into the pharmacology of an old analgesic. FASEB J. 21, 2343-2351 (2007).
2. Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K. Inhibition of cyclooxygenases by dipyrone. Br. J. Pharmacol. 151(4), 494-503 (2007).
3. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: A randomized, double blind, placebo controlled study. J. Head Face Pain 42(9), 862-871 (2002).
4. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J. Clin. Epidemiol. 51 (12), 1357-1365 (1998).
5. Arellano F, Sacristan JA. Metamizole: reassessment of its therapeutic role. Eur. J. Clin. Pharmacol. 42(2), 617-619 (1992).
6. Volz M, Kellner H-M. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br. J. Clin. Pharmacol. 10, 299S-308S (1980).
7. Levy M, Zylber-Katze E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin. Pharmacokinet. 28(3), 216-234 (1995).
8. Zylber-Katz E, Granit L, Levy M. Plasma protein binding of dipyrone metabolites in man. Eur. J. Clin. Pharmacol. 29(1), 67-71 (1985).
9. Bacracheva N, Drenska A, Gorantcheva J, Tyutyulkova N, Vlahov V. Comparative bioavailability of two oral metamizole formulations. Infuence of the acetylation phenotype. Arzneimittelforschung 45(3), 282-285 (1995).
10. Asmardi G, Jamali F. High performance liquid chromatography of dipyrone and its active metabolites in biological fuids. J. Chromatogr. 277, 183-189 (1983).
11. Sistovaris N, Pola W, Wolhoff H. Thin-layer chromatographic determination of major metamizole metabolites in serum and urine. J. Chromatogr. 274, 289-298 (1983).
12. Damm D. Simultaneous determination of the main metabolites of dipyrone by high-pressure liquid chromatography. Arzneimittelforschung 39 (11), 1415-1417 (1989).
13. Carretero I, Vadillo JM, Laserna JJ. Determination of antipyrine metabolites in human plasma by solid-phase extraction and micellar liquid chromatography. Analyst 120(6), 1729-1732 (1995).
14. Caraco Y, Zylber-Katz E, Granit L, Levy M. Validity of saliva samples for the estimation of dipyrone metabolites pharmacokinetics. Arzneimittelforschung 43 (11), 1204-1208 (1993).
15. Guidance for industry: bioanalytical method validation. Centre for Drug Evaluation and Research, US Department of Health and Human Services, US FDA, May 2001.